ArticleF1000Research2025
Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional Analysis.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HER2-positive breast carcinomas are a heterogeneous group with various clinicopathological characteristics depending on hormone receptor (HR) status. This study aimed to analyze and compare the clinical and histopathological features of HER2-positive breast carcinomas across three subgroups: Group 1: Triple-positive (ER+/PR+/HER2+), Group 2:ER-positive only (ER+/PR-/HER2+), and Group 3: HER2-enriched (ER-/PR-/HER2+). Methods: This was a single-institution, retrospective, cross-sectional study conducted over 42 months (January 2021-June 2024) at a tertiary care center comprising of 117 HER2-positive breast carcinoma cases. The demographic, clinical, and histopathological parameters were studied retrospectively. Statistical analysis was performed via SPSS Version 29.0, employing ANOVA and chi-square tests, with p < 0.05 considered significant. Results: Among 117 HER2-positive breast cancer patients, left and right breast involvement was nearly equal. Most were diagnosed via core biopsy (83.8%), with the upper outer quadrant most commonly affected (42.9%). Invasive breast carcinoma of no special type was the predominant subtype. The HER2-enriched group (Group 3) had the highest mean age (57.28 years; Conclusion: HER2-positive breast carcinomas show variability by HR status. The HER2-enriched subtype is associated with older age, higher histological grade, and advanced nodal stage, suggesting a more aggressive phenotype. Recognizing these patterns aids in accurate prognostication and guiding individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.